AI Article Synopsis
- This study investigates the safety and adverse events (AEs) related to the mRNA-1273 SARS-CoV-2 vaccine in patients who have undergone allogeneic hematopoietic stem cell transplants (HCT) within the last two years.
- A total of 54 HCT recipients were monitored, revealing that the incidence and severity of AEs were comparable to those seen in the general population, with injection site pain being the most common issue.
- The findings also indicated that female patients and those more recently transplanted were more likely to experience AEs, while the patients' perception of COVID-19 risk decreased over time.
Article Abstract
Purpose: This study aims to describe the incidence and severity of adverse events (AEs) following the mRNA-1273 SARS-CoV-2 vaccine and explore the risk perception of COVID-19 in allogeneic hematopoietic stem cell transplant (HCT) recipients.
Methods: We performed a single-center prospective study including recently transplanted (< 2 years post-infusion) allogeneic HCT recipients. AEs were assessed through phone calls and graded from 0 to 4, while COVID-19 risk perception was measured using the Brief Illness Perception Questionnaire (BIP-Q5).
Results: Fifty-four HCT recipients were evaluated. Incidence and grades of AE (94.4% and 85.2% after the first and second dose, respectively) were similar to those described in the general population. The most common AE was pain at the site of injection. Three patients (5.6%) developed a grade ≥ 3 AE. Vaccine-related cytopenias and graft-versus-host disease flares were not observed. Female sex (OR 3.94, 95% CI 1.14-13.58, p = 0.03) and time since HCT (per month since HCT: OR 1.09, 95% CI 1.01-1.18, p = 0.04) were associated with the occurrence of any AE. The patients' risk perception level of COVID-19 decreased over time (p < 0.05).
Conclusion: Our study confirms that the mRNA-1273 SARS-CoV-2 vaccine is safe in recent HCT recipients and suggests that the perceived risk of COVID-19 decreases over time.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9517991 | PMC |
| http://dx.doi.org/10.1007/s00520-022-07376-w | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Neutralizing antibodies against SARS-CoV-2 of vaccinated healthcare workers in Taiwan.
Ann Med
December 2025
Department of Pediatrics, Kawasaki Disease Center, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan.
Background: Vaccination is one of the best ways to control the SARS-CoV-2 outbreak. In Taiwan, healthcare workers were prioritized for vaccination, but the effectiveness of these vaccines for them remains unclear. Thus, it's essential to examine their neutralizing antibodies after prime-boost vaccinations.
View Article and Find Full Text PDFEffects of combined immunosuppressant and hepatitis B virus antiviral use on COVID-19 vaccination in recipients of living donor liver transplantation.
PeerJ
December 2024
Division of Hepatobiliary Surgery and Liver Transplantation, Seoul, Republic of South Korea.
Background & Aims: The global pandemic caused by the highly contagious SARS-CoV-2 virus led to the emergency approval of COVID-19 vaccines to reduce rising morbidity and mortality. However, limited research exists on evaluating the impact of these vaccines on immunocompromised individuals, such as recipients of living donor liver transplantation, highlighting the need for further studies to better understand their effectiveness in this specific population.
Methods: From June 2021, we followed up on the effectiveness of the vaccine for patients taking immunosuppressive drugs after living-donor liver transplantation (LDLT).
Local and systemic reactogenicity after mRNA and protein-based COVID-19 vaccines compared to meningococcal vaccine (MenACWY) in a UK blinded, randomized phase 2 trial (COV-BOOST).
Vaccine
January 2025
NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust and University of Southampton, Southampton, UK.
Reactogenicity, the occurrence of vaccine side effects, can impact vaccine acceptance. There is limited data comparing the reactogenicity of COVID-19 vaccines to other routinely used vaccines, such as the meningococcal conjugate vaccine (MenACWY). In a trial of UK adults, participants received a third COVID-19 vaccine dose (NVX-CoV2373, BNT162b2, or mRNA1273) alongside MenACWY as an active control.
View Article and Find Full Text PDFThe Platform Trial In COVID-19 priming and BOOsting (PICOBOO): The immunogenicity, reactogenicity, and safety of licensed COVID-19 vaccinations administered as a second booster in BNT162b2 primed individuals aged 18-<50 and 50-<70 years old.
J Infect
December 2024
Wesfarmers Centre of Vaccines and Infectious Diseases, The Kids Research Institute of Australia, Nedlands, Australia; Centre for Child Health Research, University of Western Australia, Crawley, Australia; Centre for Child Health Research, University of Western Australia, Crawley, Australia; General Paediatrics and Immunology Departments, Perth Children's Hospital, Nedlands, Australia.
Objectives: PICOBOO is a randomised, adaptive trial evaluating the immunogenicity, reactogenicity, and safety of COVID-19 booster strategies. Here, we present data for second boosters among individuals aged 18-<50 and 50-<70 years old primed with BNT162b2 until Day (D) 84.
Methods: Immunocompetent adults who had received two doses of BNT162b2 and any licensed COVID-19 booster at least three months prior were eligible.
Substantial reduction in the clinical and economic burden of disease following variant-adapted mRNA COVID-19 vaccines in immunocompromised patients in France.
Hum Vaccin Immunother
December 2024
Health Economics and Outcomes Research, Moderna France, Paris, France.
Article Synopsis
- An evaluation compared the economic and clinical impact of mRNA-1273 versus BNT162b2 COVID-19 vaccines for immunocompromised individuals aged 30 and older in France during Fall 2023 and Spring 2024.
- * The study estimated outcomes like infections, hospitalizations, deaths, long COVID cases, costs, and quality-adjusted life years (QALYs) using a decision-analytic model, finding that mRNA-1273 vaccines offer greater protection.
- * In a scenario with full vaccine coverage, mRNA-1273 could prevent nearly 4,000 infections and 326 long COVID cases, resulting in €10.1 million in societal cost-savings and 645 additional QALYs.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!